Similarly, anti-CD19 chimeric antigen receptor (CAR) T cell therapy has been approved in ALL and diffuse large B cell lymphoma based on unprecedented response rates [8–10]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.